



ShareSoc

UK Individual Shareholders Society

5 Liberty Square, Kings Hill,
West Malling, ME19 4AU
Phone: 0333-200-1595
Web: www.sharesoc.org

SHARESOC GROWTH COMPANY SEMINAR

STOCKOPEDIA FINANCIAL ANALYSIS REPORTS ON PRESENTING COMPANIES

(Don't forget ShareSoc subscribing members can get a discount off the Stockopedia service).

Important Note: These reports do not necessarily reflect the latest changes in the financial position of the companies, for example any recent fund raisings, but are primarily based on the last annual financial statements and future forecasts.

Copies of the Powerpoint presentations given by presenters at these seminars are normally added to our website, here: <https://www.sharesoc.org/seminar/> soon after the Seminar, and are available to logged in full members of ShareSoc.

Use the page below and overleaf to take notes on the presentations.

ShareSoc Investment Warning - Company Presentations

No warranty is given by ShareSoc as to the reliability, accuracy or completeness of the information provided in presentations to investors by companies or by ShareSoc representatives in seminars organised or sponsored by ShareSoc. The information given in those seminars is provided for information purposes only and does not constitute investment, legal, tax or other advice or any recommendation to buy, or sell or otherwise transact in the shares of the companies presenting. Prospective investors should take appropriate professional advice before making any investment decision, or undertake their own further research. You are reminded that investment in the stock market carries substantial risks and share prices can go down as well as up. Past performance is not necessarily an indication of future performance.

**AREC – Arecor Therapeutics****360.00p** 0.00 0%

EMS: 1k

Healthcare · Highly Speculative · Small Cap · **Momentum Trap**

Market Cap

£100.21m

Enterprise Value

£78.35m

Revenue

£1.34m

Position in Market

958th / 1,769

Quality

Value

Momentum

StockRank™

29

4

75

27

1m 3m YTD 1y 3y All

**Momentum**

Relative Strength (%)	
1m	+0.284%
3m	-5.50%
6m	+46.7%
1y	n/a
Volume Change (%)	
10d / 3m	-50.9%
Price vs... (%)	
52w High	-23.7%
50d MA	-5.73%
200d MA	+8.20%

Growth & Value

12m Forecast Rolling		Industry	Market
PE Ratio (f)	n/a		
PEG Ratio (f)	n/a		
EPS Growth (f)	n/a		
Dividend Yield (f)	0.00%		
Valuation (ttm)		Industry	Market
Price to Book Value	4.71		
Price to Tang. Book	4.72		
Price to Free Cashflow	n/a		
Price to Sales	74.75		
EV to EBITDA	n/a		

Shareholder Activity

	Buy / Hold / Sell
Institutions	
Directors	
Community	Insufficient data available

Screens Passed: 0 Long

1 Short

AREC qualifies for **James Montier 'Unholy Trinity' Screen** (Short Selling)[View Screen](#) [View Checklists](#)**Quality**

	Industry	Market
Return on Capital	-23.5%	
Return on Equity	-40.8%	
Operating Margin	-376.19%	

Financial Summary

Year End 31st Dec	2015	2016	2017	2018	2019	2020	TTM	2021E	2022E	CAGR / Avg
Total Revenue	£m		0.000	1.35	1.10	1.70	1.34	1.14	1.63	
Operating Profit	£m		0.000	-1.40	-1.57	-3.43	-5.04			
Net Profit	£m			-1.12	-1.28	-2.75	-4.81	-6.65	-9.52	
EPS Reported	p	0.000	0.000	-4.02	-4.59	-9.89	-17.3			
EPS Normalised	p	0.000	0.000	-4.02	-4.59	-9.89	-17.3	-0.330	-0.370	
EPS Growth	%									
PE Ratio	x									
PEG										
Profitability										
Operating Margin	%			-104	-142	-202	-376			-112%
ROA	%		0.000	-48.3	-40.1		-34.6			
ROCE	%		0.000	-112	-48.0	-119	-23.5			-69.9%
ROE	%		0.000	-112	-65.9	-138	-40.8			-79.0%
Cashflow										
Op. Cashflow ps	p	0.000	0.000	0.000	-1.77	-0.962	-6.67	-11.2		
Capex ps	p	0.000	0.000	0.000	0.046	0.068	0.188	0.081		
Free Cashflow ps	p	0.000	0.000	0.000	-1.82	-1.03	-6.86	-11.2		
Dividends										
Dividend ps	p	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	
Dividend Growth	%									
Dividend Yield	%						0.000	0.000	0.000	
Dividend Cover	x									
Balance Sheet										
Cash etc	£m		1.03	0.705	3.07	2.90	22.1			41.3%

Health Trend (F-Score)

3/9

**Bankruptcy Risk (Z-Score)**

48.45

**Earnings Manipulation Risk (M-Score)**

Low

Other Ratios

Leverage (ttm)	Total	- Intang	+ Pension
Gross Gearing %	1.4	1.4	1.4
Net Gearing %	-102.80	-102.96	-102.8
Cash / Assets %	94.05		94.0
Liquidity (ttm)			
Curr. Ratio			10.89
Quick Ratio			10.89
Interest Cov.			-8.74
Efficiency (ttm)			
Asset Turnover			0.10
Recs Turnover			17.12
Stock Turnover			n/a

Working Capital	£m	0.000	0.000	0.937	0.697	2.88	2.41	21.0		37.1%
Net Debt	£m	0.000	0.000	-0.452	-0.045	-2.92	-0.903	-21.9		
Net Fixed Assets	£m	0.000	0.000	0.600	0.487	0.343	0.423	0.409		-11.0%
Book Value	£m	0.000	0.000	1.33	0.670	3.21	0.774	21.3		-16.6%
Average Shares	m				28	28	28	28		
Book Value ps	p	0.000	0.000	4.78	2.41	11.5	2.78	76.4		-16.6%

FINANCIAL BRIEF: For the six months ended 30 June 2021, Arecor Therapeutics PLC revenues decreased 44% to £460K. Net loss... [See more](#)

Recent History

Latest interim period vs. prior period	Industry	Market
Sales Growth	-43.70%	
EPS Growth	n/a	
3yr Compound Annual Growth Rate	Industry	Market
Sales CAGR	n/a	
EPS CAGR	n/a	
DPS CAGR	n/a	

Graphical History


Revenue

Net Income

Normalised EPS

PE Ratio Range

Dividend Yield Range



Analyst Forecasts


Price Target: 486.00p (35.00% above Price)	31st Dec 2021			31st Dec 2022		
Est. Long Term Growth Rate:	Net Profit (£)	EPS (p)	DPS (p)	Net Profit (£)	EPS (p)	DPS (p)
Consensus Estimate	-6.65m	-0.33	0.00	-9.52m	-0.37	0.00
1m Change		+0.02			-0.02	
3m Change	+670.00k	+0.04		+121.00k	-0.02	

Analyst Consensus

2 brokers



EPS 2021 / 2022



Profile Summary

Arecor Therapeutics PLC is a United Kingdom-based biopharmaceutical company. The Company targets improving patient care by bringing medicines to market through the existing therapeutic products. It partners with global pharmaceutical and biotechnology companies to apply the Arestat technology to ... [Read more](#)

Directors

Christine Soden NID (63) | Jeremy Morgan NID (57) | Mohammad Fazeli NID (56) | Susan Lowther CFO (61) | Sarah Howell CEO (46) | Andrew Richards NEC (61) | Alan Smith NED (75) | Jan Jezek CSO | David Gerring VPR | Fiona Lawrence VPR | James Macdonald- Clink VPR

Last Annual: Dec 31, 2020
Last Interim: Jun 30, 2021
Incorporated:
Public Since:
Ex-Dividend Date:
Payment Date:
No. of Employees: 30
No. of Shareholders: 0

Sector:
Industry:
Index:
Exchange:
Asset Category:
Shares in Issue:
Free Float:
Eligible for:

Healthcare
Biotechnology & Medical Research
FTSE AIM All Share Index
LSE AIM Market
Common Stock
27,835,024
17,654,393 (63.43%)
✓ ISAs ✓ SIPPs


Address: Little Chesterford, LONDON, CB10 1XL, United Kingdom

Web:
Phone:

Auditors: Grant Thornton UK LLP

AREC Share Price Performance

Share Price	Volume	Bid - Ask	Low - High	Spread
360.00p	0	330.00p - 390.00p	0.00 - 0.00	1,667bps
Day's Change	Avg Volume	Open - Close	Range (12m)	Beta
↓ 0.00 0%	2,245	360.00 - 360.00	222.00 - 472.00	



Latest News for AREC

Jan 20, 2022

Announcement

BUSINESS UPDATE

Jan 20, 2022

Announcement

ARECOR COMMENCES US PHASE I CLINICAL TRIAL OF AT247 ULTRA-RAPID INSULIN IN COMBINATION WITH AN INSULIN PUMP

Jan 20, 2022

News

BRIEF-Arecor Therapeutics Financial Performance For FY Was In Line With Expectations

Jan 20, 2022

Announcement

Arecor Therapeutics - ARECOR PROVIDES BUSINESS UPDATE

Jan 20, 2022

Announcement

Arecor Therapeutics - ARECOR COMMENCES US PHASE I TRIAL OF AT247

Similar to AREC

Compare

☐	Chemon Inc <i>Falling Star</i>	15
☐	Contrafect <i>Sucker Stock</i>	5
☐	Cyteir Therapeutics Inc <i>Sucker Stock</i>	8
☐	Gemini Therapeutics Inc <i>Sucker Stock</i>	10
☐	Longeveron Inc <i>Neutral</i>	24
☐	Mustgrow Biologics <i>Momentum Trap</i>	35
☐	Matinas Biopharma Holdings Inc <i>Sucker Stock</i>	8
☐	Spectrum Pharmaceuticals Inc <i>Sucker Stock</i>	4

Upcoming Events for AREC

There are no upcoming events for this security

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2022